Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) saw a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 160,600 shares, a growth of 286.1% from the October 31st total of 41,600 shares. Approximately 0.8% of the company's stock are short sold. Based on an average daily volume of 78,100 shares, the days-to-cover ratio is currently 2.1 days.
Pyxis Oncology Stock Performance
PYXS stock traded down $0.07 during trading on Tuesday, hitting $1.38. 2,489 shares of the stock traded hands, compared to its average volume of 123,070. Pyxis Oncology has a 1 year low of $1.34 and a 1 year high of $13.09. The firm's 50 day moving average is $1.69 and its two-hundred day moving average is $2.27.
Get Pyxis Oncology alerts:Pyxis Oncology (NASDAQ:PYXS – Get Rating) last announced its quarterly earnings data on Tuesday, November 1st. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.09). Sell-side analysts expect that Pyxis Oncology will post -3.64 EPS for the current fiscal year.
Institutional Trading of Pyxis Oncology
Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new stake in Pyxis Oncology during the 2nd quarter valued at about $31,000. Tower Research Capital LLC TRC boosted its holdings in shares of Pyxis Oncology by 414.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 15,736 shares of the company's stock valued at $31,000 after acquiring an additional 12,676 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Pyxis Oncology by 69.0% during the 1st quarter. Bank of New York Mellon Corp now owns 32,589 shares of the company's stock valued at $132,000 after acquiring an additional 13,305 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $179,000. Finally, Millennium Management LLC purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $340,000. 71.59% of the stock is owned by hedge funds and other institutional investors.Pyxis Oncology Company Profile
(Get Rating)
Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.
Featured Stories
- Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
- Three Reasons It's Time To Get Bullish On Organigram
- Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
- Why Investors Are Eating Up Restaurant Brands International
- Zoom Video Continues to Work Through Normalization
- What an Inverted Yield Curve Means for Investors
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.